Vivek holds a PhD in synthetic biology and has extensive experience in cell engineering, assay development and translational research across academia and industry. Since joining RoukenBio's Innovation team in 2023, he has contributed to the development of innovative cellular technologies and computational platforms.
Prior to joining RoukenBio, Vivek worked as a postdoctoral researcher at the University of Edinburgh, where he developed synthetic receptor systems for applications spanning gene therapy, cell-based biosensors, inflammatory disease and bioprocess optimisation. His research also included engineering CHO cell systems to control monoclonal antibody production and designing novel cellular technologies to address complex biological challenges.
He is particularly interested in synthetic biology, cell engineering and the development of innovative cellular platforms that enable researchers to answer complex biological questions and advance therapeutic discovery.
Resources
Insights
16 December 2025
|9 min read
On-Target-Off-Tumor toxicity is a major concern in precision oncology and immuno-oncology because it means that even a highly specific therapy can harm the patient if the target antigen isn't exclusive to the tumour. Researchers aim to minimise this risk by identifying tumour-specific antigens or engineering therapies that require multiple conditions to activate, increasing safety while maintaining effectiveness. However, the story is not always that simple.
Technical Presentations
6 August 2025
|7 min read
Efficient generation of genetically modified cell lines is critical for drug development but traditionally slow and labor-intensive. RoukenBio’s LocIn system offers a targeted integration technology that significantly accelerates this process by enabling precise gene insertion without the need for subcloning, thereby improving consistency and reducing timelines.
Insights
20 May 2025
|10 min read
Our experts explore key factors in cell substrate selection and cell banking considerations to help establish robust potency assays.
